Corporate Development

Nereus is building a pipeline of novel marine-derived therapeutic agents to treat cancer, inflammatory diseases and infectious diseases. The breadth of the Nereus technology platform and the depth of its pipeline provide multiple opportunities to establish strategic relationships at different stages of the drug discovery and development value chain.

The Company is seeking development partners for its lead oncology programs, which entered clinical development in 2006. These are the tumor vascular disrupting agent NPI-2358 and the proteasome inhibitor NPI-0052. Opportunities also exist for Nereus' preclinical programs in infectious disease and inflammation.

The Company is also seeking to establish research collaborations with pharmaceutical companies. Nereus library of marine microbes will undoubtedly deliver hundreds of new pharmaceutical leads in virtually all therapeutic areas. Nereus' is very enthusiastic about the opportunity to unite its vast library of marine microbes, and the diverse chemicals produced by them, with the assays and screening tests within the discovery research laboratories of pharmaceutical companies.

For inquiries regarding strategic alliances with Nereus, please contact Dr. Charlie White by sending an email to corpdev@nereuspharm.com.